<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04930705</url>
  </required_header>
  <id_info>
    <org_study_id>7027-PL01-2021</org_study_id>
    <nct_id>NCT04930705</nct_id>
  </id_info>
  <brief_title>Study To Assess The Safety And Efficacy Of The Tempsure Flexsure Applicators For Abdominal Wrinkles</brief_title>
  <official_title>Prospective Clinical Study To Assess The Safety And Efficacy Of The Tempsure Flexsure Applicators For The Treatment Of Abdominal Wrinkles</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cynosure, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cynosure, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects will be enrolled at 1 study center. Subjects may receive 5 treatments with the&#xD;
      TempSure® device on the abdomen for wrinkles.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    This study was terminated because of a business decision.&#xD;
  </why_stopped>
  <start_date type="Actual">May 17, 2021</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correct Identification of Pre-Treatment Images Compared to Follow Up Images</measure>
    <time_frame>30 Day Follow Up</time_frame>
    <description>Blinded independent reviewers will be given pre-treatment and 30 day follow up images and will identify which image is pre-treatment, and which image was taken at the follow up. The percentage of correct images identified will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correct Identification of Pre-Treatment Images Compared to Follow Up Images</measure>
    <time_frame>90 Day Follow Up</time_frame>
    <description>Blinded independent reviewers will be given pre-treatment and 90 day follow up images and will identify which image is pre-treatment, and which image was taken at the follow up. The percentage of correct images identified will be reported.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Wrinkle</condition>
  <arm_group>
    <arm_group_label>TempSure FlexSure Applicator</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be treated with the TempSure FlexSure applicator device at each treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Treatment with TempSure Applicator</intervention_name>
    <description>Subjects will receive up to 5 treatments on the abdomen.</description>
    <arm_group_label>TempSure FlexSure Applicator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A healthy, non-smoking male or female between the age of 18 - 55 years old.&#xD;
&#xD;
          -  Willing to receive treatments with the TempSure® device.&#xD;
&#xD;
          -  Understand and accept obligation not to receive any other procedures on the treatment&#xD;
             and control area throughout the length of the study.&#xD;
&#xD;
          -  Understands and accepts the obligation and is logistically able to be present for all&#xD;
             visits.&#xD;
&#xD;
          -  Is willing to comply with all requirements of the study and sign the informed consent&#xD;
             document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Is pregnant or of child bearing potential and not using medically effective birth&#xD;
             control, or has been pregnant in the last 3 months, currently breast feeding or&#xD;
             planning a pregnancy during the study.&#xD;
&#xD;
          -  The subject is currently enrolled in an investigational drug or device trial or has&#xD;
             received an investigational drug or been treated with an investigational device within&#xD;
             in the area to be treated 6 months prior to entering this study.&#xD;
&#xD;
          -  The subject has a cut, wound, or infected skin on the area to be treated.&#xD;
&#xD;
          -  The subject is on local, oral, or systemic anesthetic agents.&#xD;
&#xD;
          -  The subject has nerve insensitivity to heat in the treatment area.&#xD;
&#xD;
          -  The subject has any condition or is in a situation which in the investigators opinion&#xD;
             may put the subject at significant risk, may confound study results or may interfere&#xD;
             significantly with the subject's participation.&#xD;
&#xD;
        Cautionary Criteria:&#xD;
&#xD;
          -  The subject has any embedded electronic device that gives or receives a signal, the&#xD;
             device should be turned off or removed prior to treatment.&#xD;
&#xD;
          -  The subject has an embedded pacemaker or implantable cardioverter defibrillator (ICD),&#xD;
             the client's cardiologist must be consulted prior to treatment.&#xD;
&#xD;
        NOTE: This device has not been tested on patients implanted with electronic devices that&#xD;
        receive or emit signals, such as: Pacemakers, Implantable Cardiac Defibrillators (ICD), or&#xD;
        Cardiac Resynchronization Therapy (CRT) devices.&#xD;
&#xD;
          -  If the neutral pad would need to be placed on a subject that has a metal plate, rod,&#xD;
             or any metal implant that could conduct heat from the Smart Handpiece or surgical&#xD;
             handpiece.&#xD;
&#xD;
          -  The subject is allergic to adhesives, such as glues on medical tape, they should be&#xD;
             alerted that a rash may occur on the neutral pad site and an over the counter solution&#xD;
             may be used to treat the area.&#xD;
&#xD;
          -  If the subject has an unhealthy expectation of the results - this is not plastic&#xD;
             surgery and all subject should be fully informed of the treatment's expected results.&#xD;
&#xD;
          -  The subject has severe laxity or sagging that causes redundant folds of tissue or&#xD;
             hanging skin in the area to be treated - this treatment will be ineffective.&#xD;
&#xD;
          -  The subject has used Accutane (Isotretinoin) six to twelve months prior to treatment,&#xD;
             as this can thin the skin and make it britlle&#xD;
&#xD;
          -  Studies of the use of the RF generator on subjects that have any of the following&#xD;
             conditions is unknown:&#xD;
&#xD;
               -  Autoimmune Disease&#xD;
&#xD;
               -  Diabetic&#xD;
&#xD;
               -  Herpes Simplex&#xD;
&#xD;
          -  Use caution when treating areas that have tattoos, permanent makeup, and permanent&#xD;
             brows.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Civiok</last_name>
    <role>Study Director</role>
    <affiliation>Cynosure, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>JUVA Skin &amp; Laser Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 11, 2021</study_first_submitted>
  <study_first_submitted_qc>June 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2021</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

